Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium SCHEMBL31135095 | 0.98 | ALDH1A1 (0.46) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL11388853 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL3244876 | 0.81 | HTT (0.48) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL12104344 | 0.79 | ALDH1A1 (0.42) | ALDH1A1HTTLMNAKDM4EMEN1 | |
| SCHEMBL3250927 | 0.79 | ALDH1A1 (0.52) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL12104164 | 0.76 | THRB (0.40) | ALDH1A1GLALMNANPSR1MAPT | |
| SCHEMBL28289553 | 0.73 | ALDH1A1 (0.53) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL31053476 | 0.73 | HTT (0.53) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL7922598 | 0.71 | ALDH1A1 (0.47) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL23220249 | 0.71 | THRB (0.63) | ALDH1A1HTTCRHBPCRHR2MCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4940816-A | Acylated cyanamide compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1990-07-10 | — | — | US | claimed |
| US-9026372-B2 | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20110117050-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110097426-A1 | Methods for Safe and Effective Treatment Using Oxazaphosphorine Drugs | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110082115-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1032556-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1032556-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999020599-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| US-4940816-A | Acylated cyanamide compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0253882-A4 | ACYLATED CYANAMIDE COMPOSITION. | UNIV MINNESOTA (US) | 1990-06-27 | — | — | EP | disclosed |
| US-4870056-A | DETERRENTS OF ALCOHOL ABUSE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1989-09-26 | — | — | US | disclosed |
| US-4726941-A | Acylated cyanamide composition for treating ethanol ingestion | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1988-02-23 | — | — | US | disclosed |
| EP-0253882-A1 | ACYLATED CYANAMIDE COMPOSITION | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1988-01-27 | — | — | EP | disclosed |
| WO-1987004348-A1 | ACYLATED CYANAMIDE COMPOSITION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1987-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117050-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | PAICS, TYMP, OTC | ALDH1A1 1737/4885HTT 1700/4885CRHBP 2114/4885 |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | ALDH1A1 858/4885HTT 20/4885CRHBP 4236/4885 |
| US-20110082115-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | PAICS, TYMP, OTC | ALDH1A1 1737/4885HTT 1700/4885CRHBP 2114/4885 |
| US-20110097426-A1 | Methods for Safe and Effective Treatment Using Oxazaphosphorine Drugs | TYMP, PAICS, ENTPD5 | ALDH1A1 1556/4885HTT 2190/4885CRHBP 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.